775 related articles for article (PubMed ID: 23533264)
21. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.
Ju YS; Lee WC; Shin JY; Lee S; Bleazard T; Won JK; Kim YT; Kim JI; Kang JH; Seo JS
Genome Res; 2012 Mar; 22(3):436-45. PubMed ID: 22194472
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic method for the detection of KIF5B-RET transformation in lung adenocarcinoma.
Go H; Jung YJ; Kang HW; Park IK; Kang CH; Lee JW; Ju YS; Seo JS; Chung DH; Kim YT
Lung Cancer; 2013 Oct; 82(1):44-50. PubMed ID: 23932363
[TBL] [Abstract][Full Text] [Related]
23. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
Matsubara D; Kanai Y; Ishikawa S; Ohara S; Yoshimoto T; Sakatani T; Oguni S; Tamura T; Kataoka H; Endo S; Murakami Y; Aburatani H; Fukayama M; Niki T
J Thorac Oncol; 2012 Dec; 7(12):1872-1876. PubMed ID: 23154560
[TBL] [Abstract][Full Text] [Related]
24. Preclinical Modeling of KIF5B-RET Fusion Lung Adenocarcinoma.
Huang Q; Schneeberger VE; Luetteke N; Jin C; Afzal R; Budzevich MM; Makanji RJ; Martinez GV; Shen T; Zhao L; Fung KM; Haura EB; Coppola D; Wu J
Mol Cancer Ther; 2016 Oct; 15(10):2521-2529. PubMed ID: 27496134
[TBL] [Abstract][Full Text] [Related]
25. Pralsetinib treatment for multiple
Cao X; Liu X; Wang S; Liu Z; Ren X; Sun D; Deng L
J Int Med Res; 2022 Jun; 50(6):3000605221105368. PubMed ID: 35751411
[TBL] [Abstract][Full Text] [Related]
26. Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells.
Hirai S; Idogawa M; Sumi T; Yamaguchi M; Niki T; Sakuma Y
Biochem Biophys Res Commun; 2022 Nov; 630():24-29. PubMed ID: 36126466
[TBL] [Abstract][Full Text] [Related]
27. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS
Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386
[TBL] [Abstract][Full Text] [Related]
28. RET rearrangements in lung adenocarcinoma and radiation.
Dacic S; Luvison A; Evdokimova V; Kelly L; Siegfried JM; Villaruz LC; Socinski MA; Nikiforov YE
J Thorac Oncol; 2014 Jan; 9(1):118-20. PubMed ID: 24346100
[TBL] [Abstract][Full Text] [Related]
29. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
[TBL] [Abstract][Full Text] [Related]
30. KIF5B/RET fusion gene analysis in a selected series of cytological specimens of EGFR, KRAS and EML4-ALK wild-type adenocarcinomas of the lung.
Borrelli N; Giannini R; Proietti A; Alì G; Pelliccioni S; Niccoli C; Lucchi M; Melfi F; Mussi A; Basolo F; Fontanini G
Lung Cancer; 2013 Sep; 81(3):377-381. PubMed ID: 23891510
[TBL] [Abstract][Full Text] [Related]
31. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
32. Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
Kim JO; Shin JY; Kim MY; Son KH; Jung CK; Kim TJ; Kim SY; Park JK; Sung SW; Bae SJ; Min HJ; Kang JH
Surg Oncol; 2018 Mar; 27(1):106-113. PubMed ID: 29549897
[TBL] [Abstract][Full Text] [Related]
33. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.
Cai W; Su C; Li X; Fan L; Zheng L; Fei K; Zhou C
Cancer; 2013 Apr; 119(8):1486-94. PubMed ID: 23378251
[TBL] [Abstract][Full Text] [Related]
34. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
35. KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
Kim JO; Lee J; Shin JY; Oh JE; Jung CK; Park JK; Sung SW; Bae SJ; Min HJ; Kim D; Park JY; Kang JH
Diagn Pathol; 2015 Aug; 10():143. PubMed ID: 26268359
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Selpercatinib in
Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
[TBL] [Abstract][Full Text] [Related]
37. Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
Ribeiro MFSA; Alessi JVM; Oliveira LJC; Gongora ABL; Sacardo KP; Zucchetti BM; Shimada AK; de Galiza Barbosa F; Feher O; Katz A
Lung Cancer; 2020 Jan; 139():9-12. PubMed ID: 31698333
[TBL] [Abstract][Full Text] [Related]
38. FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With
Kim J; Bradford D; Larkins E; Pai-Scherf LH; Chatterjee S; Mishra-Kalyani PS; Wearne E; Helms WS; Ayyoub A; Bi Y; Sun J; Charlab R; Liu J; Zhao H; Liang D; Ghosh S; Philip R; Pazdur R; Theoret MR; Beaver JA; Singh H
Clin Cancer Res; 2021 Oct; 27(20):5452-5456. PubMed ID: 34045295
[TBL] [Abstract][Full Text] [Related]
39. Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report.
Wu Y; Yan Z; Pan J; Chang X; Huang B; Luo D; Meng R; Shi H; Fan J; Nie X
World J Surg Oncol; 2022 Dec; 20(1):386. PubMed ID: 36471407
[TBL] [Abstract][Full Text] [Related]
40. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
Krajewska J; Olczyk T; Jarzab B
Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
